Active Biotech AGM Backs Reverse Share Split and Expands Capital Raising Mandate

Active Biotech AB ( (SE:ACTI) ) has shared an update.

Active Biotech’s annual general meeting approved a series of governance and capital measures, including the decision not to distribute a dividend for the 2025 financial year and to carry forward the accumulated loss, while granting discharge from liability to the board and CEO. Shareholders re-elected key board members and the auditor, confirmed existing board fee levels, refined the structure of the nomination committee based on the largest shareholders as of late September 2026, and endorsed the board’s remuneration report.

The meeting backed a 1-for-100 reverse share split, supported by amended articles of association to adjust share number limits, which will leave the company with 26,360,671 shares and a new quotient value once implemented. The board also received authorization to issue new shares and convertibles equal to up to 30 percent of the post-authorization share capital, providing financial flexibility for future funding or strategic initiatives without guaranteed pre-emptive rights for existing shareholders.

More about Active Biotech AB

Active Biotech AB is a Swedish biotechnology company listed on Nasdaq Stockholm that develops first-in-class immunomodulatory treatments targeting oncology and immunology indications with high unmet medical need and commercial potential. Its core programs include tasquinimod for myelofibrosis, laquinimod for non-infectious uveitis in partnership-driven development, and naptumomab, a targeted anti-cancer immunotherapy in phase Ib/II trials for advanced solid tumors through a collaboration with NeoTX Therapeutics.

YTD Price Performance: 60.87%

Average Trading Volume: 32,634,233

Technical Sentiment Signal: Hold

Current Market Cap: SEK206.9M

See more data about ACTI stock on TipRanks’ Stock Analysis page.